Literature DB >> 12243606

Citalopram-associated SIADH.

Teresa S Barclay1, Audrey J Lee.   

Abstract

OBJECTIVE: To report a case of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with use of citalopram in an elderly male patient and to review the English-language literature for any previous reports of SIADH or hyponatremia caused by citalopram. CASE
SUMMARY: An 87-year-old Filipino man was admitted to the hospital reporting malaise, confusion, dizziness, and falls approximately 3 weeks following an increase in his citalopram dosage from 10 to 20 mg/d. On physical examination, the patient was euvolemic and had no evidence of malignancy, cardiac, renal, or hepatic disease. Pertinent laboratory test results revealed hyponatremia, serum hypoosmolality, urine hyperosmolality, and elevated urine sodium concentration, leading to a diagnosis of SIADH. Citalopram was discontinued and fluid restrictions were instituted. The patient was discharged after his serum sodium increased from 122 to 128 mEq/L and he reported increased strength and decreased confusion. Five days after discharge, the patient denied experiencing any new falls, weakness, confusion, or lethargy. His serum sodium measured that day was 131 mEq/L; 2 months later, it was 135 mEq/L. DISCUSSION: We report the seventh case of citalopram-induced hyponatremia published in the English language and the second in a man. Review of the cases demonstrated that the onset of citalopram-induced hyponatremia or SIADH ranged from 6 to 20 days. Potential risk factors for SIADH due to citalopram included advanced age, female gender, concomitant use of medications known to cause SIADH or hyponatremia, and, possibly, higher citalopram doses.
CONCLUSIONS: Elderly patients receiving citalopram should be monitored for signs and symptoms of SIADH, especially in the first few weeks of therapy, in the presence of risk factors, and during dose escalation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243606     DOI: 10.1345/aph.1C071

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  [A 67-year-old patient with somnolence and severe hyponatraemia].

Authors:  J Seiderer; C Rust; M Menth; T Pusl; M Jung
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

2.  Posterior reversible encephalopathy syndrome with documented hyponatraemia.

Authors:  Puneet Aulakh; Eduard Fatakhov; Christopher Francis Koch; Shikha Kapil
Journal:  BMJ Case Rep       Date:  2013-07-31

Review 3.  Pituitary side effects of old and new drugs.

Authors:  Maria Chiara Zatelli; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore Degli Uberti
Journal:  J Endocrinol Invest       Date:  2014-07-29       Impact factor: 4.256

4.  Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use.

Authors:  Vivek C Kirpekar; Prashant P Joshi
Journal:  Indian J Psychiatry       Date:  2005-04       Impact factor: 1.759

Review 5.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

6.  Patient With Severe Hyponatremia Caused by Adrenal Insufficiency Due to Ectopic Posterior Pituitary Lobe and Miscommunication Between Hypothalamus and Pituitary: A Case Report.

Authors:  Maria Grammatiki; Eleni Rapti; Athanasios C Mousiolis; Maria Yavropoulou; Spyridon Karras; Afroditi Tsona; Michalis Daniilidis; John Yovos; Kalliopi Kotsa
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Severe symptomatic hyponatremia during citalopram therapy--a case report.

Authors:  Guillermo Flores; Santiago Perez-Patrigeon; Carolina Cobos-Ayala; Jesus Vergara
Journal:  BMC Nephrol       Date:  2004-01-16       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.